Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada (NCT07370766)
A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above. The real-world impact, safety and effectiveness of tildrakizumab on patients with moderate-to-severe plaque psoriasis (PsO) remain largely undocumented in Canada, despite its approval in 2018. Given Canada's diverse population, this study presents an opportunity to evaluate tildrakizumab's quality of life, safety and effectiveness in specific demographic groups, particularly those patients with Fitzpatrick scale skin type III and above. The findings from this study will help optimize care, address unmet needs, and ensure that treatment outcomes are inclusive and reflective of Canada's diverse population.
Who can join: Review the eligibility criteria below.
Location: Burlington Skin and Wellness — Burlington, Ontario
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Burlington Skin and Wellness — Burlington, Ontario
- Locke Dermatology — Hamilton, Ontario
- Panorama Dermatology Clinic — Kanata, Ontario
- Centricity Research London Victoria Multispecialty — London, Ontario
- Factor Dermatology — Ottawa, Ontario
- Saskatoon Dermatology Centre — Saskatoon, Saskatchewan
📞 Contact the Study Coordinator
Phone: (905) 849-5057
Email: dwong2014@gmail.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriasis (PsO)
- A Clinical Trial of Antiplatelets in Psoriasis — New York, New York
- The Effects of Audio-Based Therapy on Anxiety in Psoriasis — San Francisco, California
- A Study to Assess Deucravacitinib Safety in Pregnancy — La Jolla, California
- Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis — Toronto, Ontario
- Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis — Monterrey, N.L.
Explore by condition: All Psoriasis (PsO) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.